**Title**
Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial.

**Permalink**
[https://escholarship.org/uc/item/4vs136f3](https://escholarship.org/uc/item/4vs136f3)

**Journal**
Journal of neurotrauma, 35(9)

**ISSN**
0897-7151

**Authors**
Fehlings, Michael G
Kim, Kee D
Aarabi, Bizhan
et al.

**Publication Date**
2018-05-01

**DOI**
10.1089/neu.2017.5434

Peer reviewed
Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial

Michael G. Fehlings,1 Kee D. Kim,2 Bizhan Aarabi,3 Marco Rizzo,4 Lisa M. Bond,5 Lisa McKerracher,5 Alexander R. Vaccaro,6 and David O. Okonkwo7

Abstract

Traumatic spinal cord injury (SCI) is associated with a lifetime of disability stemming from loss of motor, sensory, and autonomic functions; these losses, along with increased comorbid sequelae, negatively impact health outcomes and quality of life. Early decompression surgery post-SCI can enhance patient outcomes, but does not directly facilitate neural repair and regeneration. Currently, there are no U.S. Food and Drug Administration–approved pharmacological therapies to augment motor function and functional recovery in individuals with traumatic SCI. After an SCI, the enzyme, Rho, is activated by growth-inhibitory factors and regulates events that culminate in collapse of the neuronal growth cone, failure of axonal regeneration, and, ultimately, failure of motor and functional recovery. Inhibition of Rho activation is a potential treatment for injuries such as traumatic SCI. VX-210, an investigational agent, inhibits Rho. When administered extradurally after decompression (corpectomy or laminectomy) and stabilization surgery in a phase 1/2a study, VX-210 was well tolerated. Here, we describe the design of the SPRING trial, a multicenter, phase 2b/3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of VX-210 (NCT02669849). A subset of patients with acute traumatic cervical SCI is currently being enrolled in the United States and Canada. Medical, neurological, and functional changes are evaluated at 6 weeks and at 3, 6, and 12 months after VX-210 administration. Efficacy will be assessed by the primary outcome measure, change in upper extremity motor score at 6 months post-treatment, and by secondary outcomes that include question-based and task-based evaluations of functional recovery.

Keywords: motor recovery; Rho inhibition; spinal cord injury; SPRING trial; VX-210

Introduction

Acute spinal cord injury

Current estimates indicate that 245,000–353,000 individuals who have suffered a spinal cord injury (SCI) are living in the United States, and approximately 40–54 new cases per year per million individuals occur.1,2 Common causes of SCI in the United States are motor vehicle accidents (38–42%), falls (31–33%), sports injuries (9–16%), and violence/other (9–18%).1,3 Worldwide, the estimated incidence of SCI ranges from 250,000–500,000 individuals per year,4 and approximately 2.5 million people live with an SCI.5 SCIs are often attributed to spinal cord compression and concussion that occur within a fraction of a second.5 Primary damage to the spinal cord is caused by the physical trauma, and further injury (secondary damage) is caused by downstream pathophysiological signaling cascades.6 This secondary damage is propagated through several mechanisms of action, including ischemia, excitotoxicity,
cytotoxic and vasogenic edema, lipid peroxidation/radical formation, and inflammation. Further, axonal regeneration is impeded by growth-inhibiting factors that activate an intracellular master enzyme, Rho, leading to a cascade of events culminating in collapse of the neuronal growth cone. Both primary damage to neurons and axonal projections in the spinal cord and secondary damage post-injury result in loss of motor and sensory function in patients who experience an SCI; a severe traumatic lesion to the spinal cord can result in permanent paralysis below the segmental level of the injury.

The independent daily activities of individuals who have suffered an SCI are often hampered; depending on the segmental level and injury severity, up to 24-h attendant care may be required for individuals with cervical SCI. Individuals with SCIs may also experience serious comorbidities that impact quality of life, including autonomic dysreflexia, bladder dysfunction, osteoporosis, heterotopic ossification, pressure sores, reduced immune function, chronic lifelong pain, and pulmonary and cardiovascular complications. Life expectancy of individuals with SCIs may be considerably shortened compared to age-matched controls from the general population. Because an SCI affects many aspects of life, even a partial restoration of motor function may improve patient autonomy and permit a higher quality of life.

Treatment of spinal cord injury

A recognized standard of care for traumatic SCI is immediate immobilization, prevention of neurogenic shock, intubation, oxygenation, imaging evaluation, reduction, decompression, and stabilization. These measures, which help relieve direct pressure on the spinal cord and ischemic hypoxia, may reduce secondary damage. Although treatment of an acute SCI with decompression and stabilization surgery may provide clinical benefit to patients, this procedure does not directly facilitate axonal regeneration and repair. The primary goal of acute therapy for SCI is restoration of sufficient motor function to increase autonomy. Currently, there are no approved pharmacological treatments to augment motor function after an SCI. Therefore, SCI represents an extreme unmet medical need.

VX-210, a Rho inhibitor

The inability of patients to recover motor function after an SCI stems, in part, from the failure of neurons in the central nervous system (CNS) to regrow axons post-injury. In an ideal environment, axonal regeneration and sprouting might lead to the formation of new functional connections. After an acute SCI, however, axon regeneration is impeded by a number of growth-inhibitory proteins released by myelin debris, by the glial scar, and as a result of inflammation. These factors act in concert to activate the intracellular signaling molecule, Rho, by binding to and activating specific membrane receptors. Rho overactivation leads to a cascade of events culminating in the collapse of axonal growth cones and failure of injured axons to regenerate, as well as neuronal loss. Inhibition of Rho kinase, a downstream effector of Rho, decreased neuronal injury in vitro and cortical neuronal models. Thus, inhibition of Rho activity represents a potential treatment for CNS injuries such as SCI.

VX-210, formerly referred to as BA-210 or Cethrin, is a cell-permeable derivative of the bacterial enzyme, C3 transferase, that inhibits Rho activity through covalent modification and therefore has the potential to independently block Rho-mediated axonal growth cone collapse and inhibit neuronal apoptosis post-SCI.

VX-210 is undergoing human investigation for its potential to augment motor function after acute cervical SCI.

VX-210 administration

VX-210 is administered topically in a fibrin sealant to the dura mater (extradural surface) of the spinal cord. Fibrin sealant is extensively used in spinal cord surgery for hemostasis and dural repairs. In rat and post-mortem porcine models, the concentration of VX-210 detected in spinal cord tissue after extradural application was dose dependent. Gradient levels of VX-210 were observed extending from the location of application within hours of extradural administration in both a rat SCI model and post-mortem pig spinal cord.
VX-210 in pre-clinical studies

Pre-clinical studies indicate that VX-210 has neuroregenerative and protective effects and can promote functional recovery post-SCI. In rodent models of neuronal injury, treatment with VX-210 reversed the activation of Rho in spinal cord lesions, decreased secondary tissue damage and glial scarring at the injury site, and stimulated axon regeneration and plasticity in primary cortical neurons. In a mouse model of acute SCI, VX-210 administered onto the dura mater in fibrin sealant significantly improved Basso, Beattie, and Bresnahan open field locomotor rating scale scores compared to the control group (fibrin sealant alone) at 16 days post-injury when administered at the time of injury or 24h post-injury.27

VX-210 in early clinical evaluations: Phase 1/2a trial

The safety and tolerability of VX-210 were assessed in a multicenter, open-label, phase 1/2a dose-ranging trial (NCT00500812).28,33,34 In this trial, 48 patients with acute traumatic cervical (n = 16) and thoracic (n = 32) SCIs were enrolled at nine U.S. and Canadian sites. Patients were 16–70 years of age, with an American Spinal Injury Association Impairment Scale (AIS) grade A. Patients received a single dose of VX-210 (range, 0.3–9.0 mg) applied to the dura mater of the spinal cord during decompression surgery occurring ≤7 days post-injury and were followed and assessed for 1 year after treatment.28

The most frequent treatment-emergent adverse events (AEs; by organ system) were gastrointestinal disorders (nausea, constipation, and vomiting), general disorders (pyrexia, pain, and peripheral edema), infections, and psychiatric disorders (insomnia, anxiety, depression, and altered mood). Incidence of AEs was consistent across VX-210 dose levels, and no serious AEs (SAEs) were considered by investigators to be related to treatment. The results suggested improvement in motor strength in patients with cervical SCI compared to patients in natural history studies.28 In patients with thoracic SCI, the average recovery trajectory overlapped with that of past natural history studies.5
TABLE 1. CLINICAL TRIAL SITES FOR THE SPRING TRIAL IN THE UNITED STATES AND CANADA

| State     | City            | Country |
|-----------|-----------------|---------|
| Arizona   | Tucson          | USA     |
| California| Los Angeles     | USA     |
| California| Orange          | USA     |
| California| Sacramento      | USA     |
| Connecticut| New Haven    | USA     |
| Florida   | Jacksonville    | USA     |
| Florida   | Tampa           | USA     |
| Georgia   | Atlanta         | USA     |
| Georgia   | Savannah        | USA     |
| Illinois  | Chicago         | USA     |
| Iowa      | Iowa City       | USA     |
| Kansas    | Kansas City     | USA     |
| Maryland  | Baltimore       | USA     |
| Massachusetts| Boston     | USA     |
| Michigan  | Ann Arbor       | USA     |
| Minnesota| Minneapolis    | USA     |
| Mississippi| Jackson       | USA     |
| Missouri  | St Louis        | USA     |
| New Jersey| Camden         | USA     |
| Ohio      | Cleveland       | USA     |
| Ohio      | Columbus        | USA     |
| Ohio      | Toledo          | USA     |
| Pennsylvania| Hershey     | USA     |
| Pennsylvania| Philadelphia | USA     |
| Pennsylvania| Pittsburgh  | USA     |
| Utah      | Salt Lake City  | USA     |
| Washington| Seattle         | USA     |
| Alberta   | Calgary         | Canada  |
| British Columbia| Vancouver   | Canada  |
| Nova Scotia| Halifax       | Canada  |
| Ontario   | Ottawa          | Canada  |
| Ontario   | Toronto         | Canada  |
| Québec    | Montréal        | Canada  |
| Québec    | Québec City     | Canada  |
| Saskatchewan | Saskatoon  | Canada  |

Site and clinical trial information can be found at: www.vertexscitrial.com or www.clinicaltrials.gov (NCT026698949).

measure of clinically meaningful neurological improvement. Given that each of the muscles evaluated in the UEMS assessment is critical for daily function, small increases in UEMS can correspond to clinically meaningful improvements in functional recovery. Total motor score is not appropriate because 1) it assesses contraction strength of 10 key muscles in the upper and lower extremities on each side of the body and does not evaluate muscle groups by the potential for function or the functional value of an increase in score, and 2) the mechanism of action and target engagement would dictate a primary assessment focused on regeneration and sprouting local to the injury site. Secondary endpoints include examination of the effects of VX-210 on functional recovery by both question- and task-based assessments, change in AIS grade, and change in motor level.

Inclusion/exclusion criteria

Key inclusion and exclusion criteria for the study are summarized in Table 2. Eligible patients are between 14 and 75 years of age and have an acute traumatic cervical SCI. Patients must have an AIS grade of A or B; a motor level of C4, C5, C6, or C7 on each side as determined by a formal International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) examination; and a screening UEMS of ≤16 points on each side (maximum total 32/50). Patients with AIS grade A and a C4 motor level on both sides must have ≥1 point of motor activity between C5 and T1 on at least one side; patients with AIS grade B and a C4 motor level on both sides must have ≥1 point of motor activity between C5 and C7 on at least one side. Patients must be scheduled to undergo spinal decompression/stabilization surgery commencing within 72 h after the initial injury, and computed tomography (CT) or magnetic resonance imaging (MRI) results must be consistent with the patient’s neurological deficit. The subset of patients with C7 SCI added by protocol amendment was included to expand the range of eligible patients for the SPRING trial without compromising the primary analysis of change in UEMS.

Exclusion criteria include body mass index ≥40 kg/m²; acute SCI from a penetrating gunshot or stab wound, nontraumatic SCI, brachial plexus injury, complete spinal cord transection, or multifocal SCI ≥1 upper extremity muscle group untestable during screening ISNCSCI examination; unconsciousness or mental impairment that precludes reliable screening ISNCSCI examination; inability to undergo decompression/stabilization surgery commencing within 72 h post-injury; known immunodeficiency, including human immunodeficiency virus (HIV) or the use of immunosuppressive or cancer chemotherapeutic drugs; breastfeeding or pregnancy; history of an adverse reaction to a fibrin sealant or its components; any significant medical or psychiatric comorbidities (e.g., neurological, cardiac, respiratory, hepatic, renal, bleeding/coagulation disorder, and active malignancy) that would significantly increase the risk of trial enrollment and/or significantly interfere with trial outcomes or assessments, as judged by the investigator, or participation in any other clinical study for acute SCI without approval by the study sponsor.

Study design

In this double-blind, placebo-controlled study, each patient receives either a single 9-mg dose of VX-210 in fibrin sealant or a placebo (buffer solution) in fibrin sealant. The one-time treatment or placebo is administered by a surgeon directly onto the dura mater of the spinal cord at the site of injury during spinal cord decompression and internal stabilization surgery (Fig. 2). Patients are randomized to the 9-mg or placebo groups at a 1:1 ratio using an interactive Web or voice response system, with stratification by age (<30 vs. ≥30 years) and AIS grade (A vs. B with sacral pinprick preservation vs. B without sacral pinprick preservation). VX-210 and placebo are supplied in 2.0-mL glass vials, and the blinded study drug labeling is prepared and administered processes. All clinical site personnel are blinded throughout the study; unblinding of an individual patient’s treatment by the investigator is limited to medical emergencies or urgent clinical situations in which knowledge of the patient’s study treatment is necessary for clinical management. Follow-up assessments of recovery in VX-210-treated versus placebo-treated patients are conducted at 6 weeks and 3, 6, and 12 months post-treatment (Table 3). Medical, neurological, and functional changes are evaluated at pre-defined time points, and serum samples are collected for pharmacokinetic, biomarker, genetic, and immunological analyses. In the phase 1/2a trial, the 9-mg dose was the highest concentration tested, had a safe and tolerable safety profile, and was chosen to maximize target engagement.

Study endpoints

The primary endpoint of this study is the change from baseline in UEMS at 6 months post-treatment. UEMS is a portion of the ISNCSCI neurological assessment that focuses on the hand and arm strength most relevant to individuals with a cervical SCI. Muscle contraction strength is graded in five key arm and hand muscle...
Table 2. Eligibility Criteria: Phase 2b/3 SPRING Trial

| Key inclusion criteria | Key exclusion criteria |
|------------------------|------------------------|
| **Patient characteristics** | **Patient characteristics** |
| Injury | Neurological impairment |
| Acute traumatic cervical SCI | Motor level of C4, C5, C6, or C7 on each side |
| | – Screening UEMS score must be ≤16 points on each side. |
| | – Patients with AIS grade A and a C4 motor level on both sides must have at least 1 point of motor activity between C5 and T1 on at least 1 side. |
| | – Patients with AIS grade B and a C4 motor level on both sides must have at least 1 point of motor activity between C5 and C7 on at least 1 side. |
| **Decompression/stabilization** | **Decompression/stabilization** |
| | AIS grade A or B |
| | Scheduled and planned to undergo spinal cord decompression/stabilization surgery commencing within 72 h post-injury |
| **Other** | Inability to undergo decompression/stabilization surgery commencing within 72 h post-injury |
| | Breastfeeding or pregnancy |
| | Acute SCI from gunshot or penetrating/stab wound; nontraumatic SCI; brachial plexus injury; complete spinal cord transection; or multi-focal SCI |
| | ≥1 upper extremity muscle group untestable during screening ISNCSCI examination |
| | Unconsciousness or other mental impairment that precludes reliable ISNCSCI examination |

AIS, American Spinal Injury Association Impairment Scale; CT, computed tomography; HIV, human immunodeficiency virus; ISNCSCI, International Standards for Neurological Classification of Spinal Cord Injury; MRI, magnetic resonance imaging; SCI, spinal cord injury; UEMS, upper extremity motor score.

groups on each side of the body from 0 (total paralysis) to 5 ([normal] active movement, full range of motion against gravity, and full resistance in a functional muscle position expected from an otherwise unimpaired person), for a total possible UEMS of 50. Change from baseline to 6 months in UEMS for the VX-210 9-mg group will be compared to that of the placebo group for the primary evaluation of efficacy.

Secondary endpoints evaluating functional recovery include 1) the Spinal Cord Independence Measure III (SCIM III) self-care subscore (a question-based evaluation of a patient’s ability to feed, dress, groom, and bathe independently on a daily basis) at 6 months post-treatment; 2) the capabilities of upper extremity test (CUE-T) score (an evaluation of a patient’s ability to perform specific functional movements or tasks with the arms and hands, such as grasping a pencil, pushing, or lifting a weight) at 6 months post-treatment; and 3) the graded redefined assessment of strength, sensibility, and prehension (GRASSP) quantitative prehension score (an assessment of a patient’s ability to perform specific functions with the arms, hands, and fingers, such as turning a key in a lock or pouring water in a cup) at 6 months post-treatment.

Secondary endpoints evaluating neurological recovery include AIS grade conversion and motor level change from baseline to 6 months post-treatment, which are both derivatives of the ISNCSCI neurological assessment. Pharmacokinetic parameters of VX-210 will also be evaluated. The ISNCSCI, SCIM III, CUE-T, and GRASSP assessments are conducted by independent trained assessors. All efforts are made to use the same assessor for a given efficacy assessment for a given patient.

Safety evaluations include AEs, vital signs, electrocardiograms, clinical laboratory tests (i.e., serum chemistry, hematology, coagulation, and urinalysis), physical examinations, surgical site examinations, and immunogenicity measures. Safety and tolerability data will be reviewed by an independent data monitoring committee to ensure the safety of patients in the study.

Interim analysis

An interim analysis will be conducted when 33% of enrolled patients have completed the 6-month follow-up visit, and the study may be stopped for futility depending on the results of this interim analysis. An independent data monitoring committee will conduct the review and make a recommendation to the study sponsor on the topic of futility.

Statistical analysis

The null hypothesis to be tested is that the mean change from baseline in UEMS at 6 months post-treatment is the same for the 9-mg VX-210 and placebo. This null hypothesis will be tested at a two-sided significance level (α=0.05). Using a standard deviation of 6.0, if the 9-mg VX-210 group improves in UEMS by 4 points more than the placebo group (a clinically meaningful difference), the approximately 100 study patients (~50 patients/group) will provide ≥80% power to detect a statistically significant treatment effect for the 9-mg VX-210 group compared to placebo. The primary analysis will include those who prematurely terminate before the 6-month follow-up.

To control the type I error rate, a hierarchical testing procedure will be used for the important efficacy endpoints. The first endpoint in the testing hierarchy will be the primary endpoint (change from...
| Event/assessment                              | Screening | Surgery | Post-surgery | 6-week follow-up (±7 days) | 3-month follow-up (±7 days) | 6-month follow-up (±7 days) | 12-month follow-up (±7 days) | Early termination | Safety follow-up 28 (±3) days after treatment |
|----------------------------------------------|-----------|---------|-------------|-----------------|-----------------|-----------------|-----------------|---------------|------------------------------------------|
| AEs and past and concomitant medications    | Continuous from signing of ICF through the last study visit |
| Efficacy assessments                         |           |         |             |                  |                  |                  |                  |               |                                          |
| ISNCSCI examination                          | X         |         |             |                  |                  |                  |                  |               |                                          |
| SCIM III                                     | X         |         |             |                  |                  |                  |                  |               |                                          |
| GRASSP quantitative prehension               | X         |         |             |                  |                  |                  |                  |               |                                          |
| CUE-T                                        |           |         |             |                  |                  |                  |                  |               |                                          |
| Follow-up questionnaire                      |           |         |             |                  |                  |                  |                  |               |                                          |
| SF-36                                        |           |         |             |                  |                  |                  |                  |               |                                          |
| EQ-5D-5L                                     |           |         |             |                  |                  |                  |                  |               |                                          |
| Hospitalizations                             | Continuous from signing of ICF through the last study visit |
| Study drug administration                    |           |         |             |                  |                  |                  |                  |               |                                          |
| VX-210 or placebo                            |           |         |             |                  |                  |                  |                  |               |                                          |
| Pharmacokinetic assessments                  |           |         |             |                  |                  |                  |                  |               |                                          |
| Serum samples for PK                         | X         |         |             |                  |                  |                  |                  |               |                                          |

*aResults of assessments performed as part of standard of care (except for ISNCSCI examination) within 72 h after initial injury and before signing of the ICF may be carried forward as screening results.
*bSurgery refers to the spinal decompression/stabilization surgery that commences within 72 h after initial injury, during which the study drug (VX-210 or placebo) is administered in a fibrin sealant.
*cPost-surgery assessments are performed within 7 days of completion of surgery.
*dFollow-up assessments of recovery are conducted at 6 weeks, 3 months, 6 months, and 12 months after treatment.
*eThe safety follow-up visit is required in addition to the early termination visit only for patients who prematurely terminate from the study before day 28 after treatment. Patients who prematurely terminate from the study after day 28 are only required to complete the early termination visit.
*fSerum samples for PK analyses are collected at ≤72 h (before surgery) and at 3, 6, 12, 24, and 48 h after treatment and at the time of any SAE occurring within 3 days after treatment. The acceptable window for the post-treatment PK sampling time points is ±30 min.

AE, adverse event; CUE-T, capabilities of upper extremity test; EQ-5D-5L, 5-level European Quality of Life–5 Dimensions Questionnaire; GRASSP, graded redefined assessment of strength, sensibility and prehension; ICF, informed consent form; ISNCSCI, International Standards for Neurological Classification of Spinal Cord Injury; PK, pharmacokinetic; SAE, serious AE; SCIM, Spinal Cord Independence Measure; SF-36, Short Form 36 Health Survey.
baseline in UEMS at 6 months post-treatment). The second endpoint in the testing hierarchy will be the SCIM III self-care subscore at 6 months post-treatment. Treatment effects will be analyzed for each time point.

Ethics and informed consent

The study is being conducted in accord with the current International Conference on Harmonisation Guideline for Good Clinical Practice (ICH GCP), which is consistent with the ethical principles founded in the Declaration of Helsinki, and in accord with local applicable laws and regulations. An institutional review board (IRB) or independent ethics committee (IEC) reviews all appropriate study documentation to safeguard the rights, safety, and well-being of the patients. The study is only conducted at sites where IRB/IEC approval has been obtained.

After the study has been fully explained, the patient (or a witness or legally appointed and authorized representative) signs and dates an informed consent form before study participation. The method of obtaining and documenting the informed consent and assent (if applicable) and the contents of the consent comply with the ICH GCP and all applicable laws and regulations.

Conclusions

Substantial preclinical data support Rho overactivation as a key step in the inhibition of motor neurite outgrowth and promotion of neuronal apoptosis post-SCI. Inhibition of Rho thus represents a potential treatment for SCI. VX-210 is an investigational inhibitor of Rho. The phase 2b/3 SPRING trial (ClinicalTrials.gov identifier: NCT02669849) tests the hypothesis that VX-210 applied to the (extradural) dura mater diffuses into the spinal cord and augments motor recovery after acute cervical SCI. The SPRING trial is currently enrolling patients with acute cervical SCI throughout the United States and Canada.

Acknowledgments

The authors thank and acknowledge the participants, researchers, and participating study sites. Editorial assistance was provided under the direction of the authors by William S. Turner, PhD, Susan Schade-Bijur, PhD, CMPP, and Jennifer Rossi, MA, ELS, MedThink SciCom, and funded by Vertex Pharmaceuticals Incorporated.

Author Disclosure Statement

Kee D. Kim has served on steering committees for spinal cord injury trials for Vertex Pharmaceuticals Incorporated and InVivo Therapeutics. Lisa M. Bond is an employee of BioAxone Biosciences, Inc, and may hold stock and/or stock options in the company and has received consulting fees from Vertex Pharmaceuticals Incorporated. Lisa McKerracher is an employee of BioAxone Biosciences, Inc, and has three issued patents licensed to Vertex Pharmaceuticals Incorporated (US7141428, US6855688, and US7795218). Marco Rizzo is an employee of Vertex Pharmaceuticals Incorporated and may hold stock and/or stock options in the company. Alexander R. Vaccaro holds stock and/or stock options in Replication Medica, Globus, Paradigm Spine, Stout Medical, Progressive Spinal Technologies, Advanced Spinal Intellectual Properties, Spine Medica, Computational Biodynamics, Spinology, Flagship Surgical, Cytonics, Bonovo Orthopaedics, Electrocore, Gamma Spine, FlowPharma, Rothman Institute and Related Properties, Innovative Surgical Design, Vertiflex, Avaz Surgical, Prime Surgeons, Dimension Orthotics, LLC, Vexim, SpineWave, Atlas Spine, Insight Therapeutics, Nuvasive, and Parvizi Surgical Innovation; has received consulting fees or royalties from DePuy, Medtronic, Stryker Spine, Globus, Stout Medical, Aesculap, Gerson Lehrman Group, Guidepoint Global, Medacorp, Innovative Surgical Design, Orthobullets, Thieme, Jaypee, Elsevier, Taylor Francis/Hodder and Stoughton, Expert Testimony, Vexim, SpineWave, Atlas Spine, and Nuvasive; is a board member of Progressive Spinal Technologies, Flagship Surgical, AO Spine, Innovative Surgical Design, Prime Surgeons, Spine Therapy Network, Inc, and Parvizi Surgical Innovation; and serves as an editor for ClinicalSpineSurgery and Spine Journal. Michael G. Fehlings, Bizhan Araabi, and David O. Okonkwo have no conflicts of interest to disclose.

Aspects of the original study design for this trial were presented, in part, at the 34th Annual National Neurotrauma Symposium, June 26–29, 2016, Lexington, Kentucky.

References

1. National Spinal Cord Injury Statistical Center. Spinal cord injury facts and figures at a glance. 2017. Available at: https://www.nscisc.uab.edu. Accessed July 14, 2017.
2. Singh, A., Tetreault, L., Kalsi-Ryan, S., Nouri, A., and Fehlings, M.G. (2014). Global prevalence and incidence of traumatic spinal cord injury. Clin. Epidemiol, 6, 309–331.
3. Araabi, B., Sansur, C.A., Ibrahimi, D.M., Simard, J.M., Hersh, D.S., Le, E., Diaz, C., Massetti, J., and Akhtar-Danesh, N. (2017). Intradurally lesion length on postoperative magnetic resonance imaging is a strong predictor of ASIA impairment scale grade conversion following decompressive surgery in cervical spinal cord injury. Neurosurgery 80, 610–620.
4. World Health Organization. Spinal cord injury: fact sheet no. 384. 2013. Available at: http://www.who.int/mediacentre/factsheets/fs384/en/. Accessed July 14, 2017.
5. Fehlings, M.G., Vaccaro, A., Wilson, J.R., Singh, A., Cadotte, D.W., Harrop, J.S, Araabi, B., Shahfiey, C, Dvorak, M., Fisher, C., Arnold, P., Massicotte, E.M., Lewis, S., and Rampaedaur, R. (2012). Early versus delayed decompression for traumatic spinal cord injury: results of the surgical timing in acute spinal cord injury study (STASCIS). PLoS One 7, e29357.
6. Hausmann, O.N. (2003). Post-traumatic inflammation following spinal cord injury. Spinal Cord 41, 369–378.
7. Schwab, J.M., Brechtel, K., Mueller, C.A., Failli, V., Kaps, H.-P., Tuli, S.K., and Schluesener, H.J. (2006). Experimental strategies to promote spinal cord regeneration—an integrative perspective. Prog. Neurobiol. 78, 91–116.
8. Schwab, M.E. (2004). Nogo and axon regeneration. Curr. Opin. Neurobiol. 14, 118–124.
9. McKerracher, L., and David, S. (2004). Easing the brakes on spinal cord injury. Nat. Med. 10, 1052–1053.
10. Dubreuil, C.I., Winton, M.J., and McKerracher, L. (2003). Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J. Cell Biol. 162, 233–243.
11. Madura, T., Yamashita, T., Kubo, T., Fujitani, M., Hosokawa, K., and Tohyama, M. (2004). Activation of Rho in apoptotic neurons in the SCI. J. Neurosci. 24, 331–339.
12. Shibata, A., Wright, M.V., David, S., McKerracher, L., Braun, P.E., and Kater, S.B. (1998). Unique responses of differentiating neuronal growth cones to inhibitory cues presented by oligodendrocytes. J. Cell Biol. 142, 191–202.
13. Dumont, R.J., Okonkwo, D.O., Verma, S., Hurlbert, R.J., Boulos, P.T., Ellegala, D.B., and Dumont, A.S. (2001). Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin. Neuropharmacol. 24, 254–266.
14. Steves, J.D., Lammertime, D.P., Kramer, J.L., Kleitman, N., Kalsi-Ryan, S., Jones, L., Curt, A., Blight, A.R., and Anderson, K.D. (2012). Outcome measures for acute/subacute cervical sensorimotor complete (AIS-A) spinal cord injury during a phase 2 clinical trial. Top. Spinal Cord Inj. Rehabil. 18, 1–14.
15. Fawcett, J.W., Curt, A., Steves, J.D., Coleman, W.P., Tuszyński, M.H., Lammertime, D., Bartlett, P.F., Blight, A.R., Dietz, V., Diunno, J., Dokkin, B.H., Hayton, L.A., Ellaway, P.H., Fehlings, M.G., Privat, A., Grossman, R., Guest, J.D., Kleitman, N., Namakura, M., Gaviria, M., and Short, D. (2007). Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous
16. Krassiovkov, A.V., Furlan, J.C., and Fehlings, M.G. (2003). Autonomic dysreflexia in acute spinal cord injury: an under-recognized clinical entity. J. Neurotrauma 20, 707–716.

17. Ackery, A., Tator, C., and Krassiovkov, A. (2004). A global perspective on spinal cord injury epidemiology. J. Neurotrauma 21, 1355–1370.

18. Cruse, J.M., Lewis, R.E., Diliglou, S., Roe, D.L., Wallace, W.F., and Chen, R.S. (2000). Review of immune function, healing of pressure ulcers, and nutritional status in patients with spinal cord injury. J. Spinal Cord Med. 23, 129–135.

19. Krassiovkov, A.V., Furlan, J.C., and Fehlings, M.G. (2003). Medical co-morbidities, secondary complications, and mortality in elderly with acute spinal cord injury. J. Neurotrauma 20, 391–399.

20. Moore, P.D., Gorgey, A.S., Wade, R.C., Khalil, R.E., Lavis, T.D., Khan, R., and Adler, R.A. (2016). Neuroumuscular systemic stimulation and testosteronone did not influence heterotopic ossification size after spinal cord injury: a case series. World J. Clin. Cases 4, 172–176.

21. Zakrasek, E.C., Nelson, J.L., Kosarchuk, J.J., Crew, J.D., Ferguson, A.R., and McKenna, S.L. (2017). Pulmonary outcomes following specialized respiratory management for acute cervical spinal cord injury: a retrospective analysis. Spinal Cord 55, 559–565.

22. Bonner, S., and Smith, C. (2013). Initial management of acute spinal cord injury. Contin. Educ. Anaesth. Crit. Care Pain 13, 224–231.

23. Furlan, J.C., Noonan, V., Cadotte, D.W., and Fehlings, M.G. (2011). Timing of decompressive surgery of spinal cord after traumatic spinal cord injury: an evidence-based examination of pre-clinical and clinical studies. J. Neurotrauma 28, 1371–1399.

24. Filbin, M.T. (2003). Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat. Rev. Neurosci. 4, 703–713.

25. McKerracher, L., and Guertin, P. (2013). Rho as a target to promote repair: translation to clinical studies with Cethrin. Curr. Pharm. Des. 19, 4440–4445.

26. Hemphill, M.A., Dabiri, B.E., Gabriele, S., Kerscher, L., Franck, C., Goss, J.A., Alford, P.W., and Parker, K.K. (2011). A possible role for integrin signaling in diffuse axonal injury. PLoS One 6, e22899.

27. Lord-Fontaine, S., Yang, F., Diep, Q., Dergham, P., Munzer, S., Tremblay, P., and McKerracher, L. (2008). Local inhibition of Rho signaling by cell-permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. J. Neurotrauma 25, 1309–1322.

28. Fehlings, M.G., Theodore, N., Harrop, J., Maires, G., Kuntz, C., Shafrey, C.L., Kwon, B.K., Chapman, J., Yee, A., Tighe, A., and McKerracher, L. (2011). A phase I/IIA clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J. Neurotrauma 28, 787–796.

29. Fehlings, M.G., Bond, L.M., and Rizzo, M. (2016). Rho inhibitor VX-210 in acute traumatic cervical spinal cord injury: design of the phase 2b/3 spinal cord injury Rho inhibition investigatIOn (SPRING) trial. Poster presented at the 34th Annual Symposium of the National Neurotrauma Society, June 26–29, Lexington, KY.

30. Dergham, P., Grazman, B., Essagian, G., Sibon, H., Lobell, W.D., and McKerracher, L. (2002). Rho signaling pathway targeted to promote spinal cord repair. J. Neurosci. 22, 6570–6577.

31. Fournier, A.E., Takizawa, B.T., and Strittmatter, S.M. (2003). A phase I/IIA clinical trial of a recombinant Rho activator that promotes neurite growth. Mol. Cell. Neurosci. 24, 913–925.

32. Bond, L.M., and McKerracher, L. (2014). Cervical spinal cord injury: tailoring clinical trial endpoints to reflect meaningful functional improvements. Neural Regen. Res. 9, 1493–1497.

33. McKerracher, L., and Anderson, K.D. (2013). Analysis of recruitment and outcomes in the phase I/IIA Cethrin clinical trial for acute spinal cord injury. J. Neurotrauma 30, 1795–1804.

34. Study to assess the efficacy and safety of VX-210 in subjects with acute traumatic cervical spinal cord injury. 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT02669849. Accessed July 14, 2017.

35. E-mail: michael.fehlings@uhn.ca

Address correspondence to: Michael G. Fehlings, MD, PhD, FRSC, FACS
Division of Neurosurgery
University of Toronto
399 Bathurst Street
Suite 4W-449
Toronto, Ontario M5T 2S8
Canada